Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

482 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical Impact of Circulating Tumor RAS and BRAF Mutation Dynamics in Patients With Metastatic Colorectal Cancer Treated With First-Line Chemotherapy Plus Anti-Epidermal Growth Factor Receptor Therapy.
Maurel J, Alonso V, Escudero P, Fernández-Martos C, Salud A, Méndez M, Gallego J, Rodriguez JR, Martín-Richard M, Fernández-Plana J, Manzano H, Méndez JC, Zanui M, Falcó E, Gil-Raga M, Aparicio J, Feliu J, García-Albéniz X, Torres F, Rojo F, Bellosillo B, Mendiola M, Fernández V, Reig O, Claes B, Maertens G, Sablon E, Jacobs B, Montagut C. Maurel J, et al. Among authors: feliu j. JCO Precis Oncol. 2019 Dec;3:1-16. doi: 10.1200/PO.18.00289. JCO Precis Oncol. 2019. PMID: 35100697
Irinotecan plus raltitrexed as first-line treatment in advanced colorectal cancer: a phase II study.
Feliu J, Salud A, Escudero P, López-Gómez L, Pericay C, Castañón C, de Tejada MR, Rodríguez-García JM, Martínez MP, Martín MS, Sánchez JJ, Barón MG; Oncopaz Cooperative Group and Associated Hospitals. Feliu J, et al. Br J Cancer. 2004 Apr 19;90(8):1502-7. doi: 10.1038/sj.bjc.6601713. Br J Cancer. 2004. PMID: 15083176 Free PMC article. Clinical Trial.
Phase II study of UFT and oxaliplatin in first-line treatment of advanced colorectal cancer.
Feliu J, Vicent JM, García-Girón C, Constela M, Fonseca E, Aparicio J, Lomas M, Antón-Aparicio L, Dorta FJ, Gonzalez-Baron M; Oncopaz Cooperative Group and Associated Hospitals. Feliu J, et al. Br J Cancer. 2004 Nov 15;91(10):1758-62. doi: 10.1038/sj.bjc.6602217. Br J Cancer. 2004. PMID: 15505621 Free PMC article. Clinical Trial.
Phase II randomised trial of raltitrexed-oxaliplatin vs raltitrexed-irinotecan as first-line treatment in advanced colorectal cancer.
Feliu J, Castañón C, Salud A, Mel JR, Escudero P, Pelegrín A, López-Gómez L, Ruiz M, González E, Juárez F, Lizón J, Castro J, González-Barón M; Oncopaz Cooperative Group, Spain. Feliu J, et al. Br J Cancer. 2005 Nov 28;93(11):1230-5. doi: 10.1038/sj.bjc.6602860. Br J Cancer. 2005. PMID: 16265344 Free PMC article. Clinical Trial.
Design and endpoints of clinical and translational trials in advanced colorectal cancer. a proposal from GROUP Español Multidisciplinar en Cancer Digestivo (GEMCAD).
Carrera G, Garcia-Albeniz X, Ayuso JR, Aparicio J, Castells A, Codony-Servat J, Feliu J, Fuster D, Gallego R, Pagés M, Torres F, Maurel J. Carrera G, et al. Among authors: feliu j. Rev Recent Clin Trials. 2011 May;6(2):158-70. doi: 10.2174/157488711795177868. Rev Recent Clin Trials. 2011. PMID: 21241233 Review.
A combined strategy of SAGE and quantitative PCR Provides a 13-gene signature that predicts preoperative chemoradiotherapy response and outcome in rectal cancer.
Casado E, García VM, Sánchez JJ, Blanco M, Maurel J, Feliu J, Fernández-Martos C, de Castro J, Castelo B, Belda-Iniesta C, Sereno M, Sánchez-Llamas B, Burgos E, García-Cabezas MÁ, Manceñido N, Miquel R, García-Olmo D, González-Barón M, Cejas P. Casado E, et al. Among authors: feliu j. Clin Cancer Res. 2011 Jun 15;17(12):4145-54. doi: 10.1158/1078-0432.CCR-10-2257. Epub 2011 Apr 5. Clin Cancer Res. 2011. PMID: 21467161
482 results